Natalizumab in acute ischemic stroke (ACTION II): A randomized, placebo-controlled trial

OBJECTIVE: We evaluated the effect of 2 doses of natalizumab on functional outcomes in patients with acute ischemic stroke (AIS). METHODS: In this double-blind phase 2b trial, patients with AIS aged 18–80 years with NIH Stroke Scale scores of 5–23 from 53 US and European sites were randomized 1:1:1...

Descripción completa

Detalles Bibliográficos
Autores principales: Elkind, Mitchell S.V., Veltkamp, Roland, Montaner, Joan, Johnston, S. Claiborne, Singhal, Aneesh B., Becker, Kyra, Lansberg, Maarten G., Tang, Weihua, Kasliwal, Rachna, Elkins, Jacob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Null Hypothesis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668547/
https://www.ncbi.nlm.nih.gov/pubmed/32591475
http://dx.doi.org/10.1212/WNL.0000000000010038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668547/
https://www.ncbi.nlm.nih.gov/pubmed/32591475
http://dx.doi.org/10.1212/WNL.0000000000010038

Ejemplares similares